Literature DB >> 27242678

Hospital Acquired Pneumonia Due to Achromobacter spp. in a Geriatric Ward in China: Clinical Characteristic, Genome Variability, Biofilm Production, Antibiotic Resistance and Integron in Isolated Strains.

Chao Liu1, Fei Pan2, Jun Guo3, Weifeng Yan1, Yi Jin1, Changting Liu4, Long Qin1, Xiangqun Fang4.   

Abstract

BACKGROUND: Hospital-acquired pneumonia (HAP) due to Achromobacter has become a substantial concern in recent years. However, HAP due to Achromobacter in the elderly is rare.
METHODS: A retrospective analysis was performed on 15 elderly patients with HAP due to Achromobacter spp., in which the sequence types (STs), integrons, biofilm production and antibiotic resistance of the Achromobacter spp. were examined.
RESULTS: The mean age of the 15 elderly patients was 88.8 ± 5.4 years. All patients had at least three underlying diseases and catheters. Clinical outcomes improved in 10 of the 15 patients after antibiotic and/or mechanical ventilation treatment, but three patients had chronic infections lasting more than 1 year. The mortality rate was 33.3% (5/15). All strains were resistant to aminoglycosides, aztreonam, nitrofurantoin, and third- and fourth-generation cephalosporins (except ceftazidime and cefoperazone). Six new STs were detected. The most frequent ST was ST306. ST5 was identified in two separate buildings of the hospital. ST313 showed higher MIC in cephalosporins, quinolones and carbapenems, which should be more closely considered in clinical practice. All strains produced biofilm and had integron I and blaOXA-114-like . The main type was blaOXA-114q . The variable region of integron I was different among strains, and the resistance gene of the aminoglycosides was most commonly inserted in integron I. Additionally, blaPSE-1 was first reported in this isolate.
CONCLUSION: Achromobacter spp. infection often occurs in severely ill elders with underlying diseases. The variable region of integrons differs, suggesting that Achromobacter spp. is a reservoir of various resistance genes.

Entities:  

Keywords:  Achromobacter; biofilm; elderly; hospital-acquired pneumonia; integron

Year:  2016        PMID: 27242678      PMCID: PMC4860489          DOI: 10.3389/fmicb.2016.00621

Source DB:  PubMed          Journal:  Front Microbiol        ISSN: 1664-302X            Impact factor:   5.640


Introduction

Achromobacter is a ubiquitous, non-fermenting, gram-negative bacterium that lives in soil and aquatic environments. In recent years, many studies have shown that this opportunistic pathogen can lead to various infections, such as sepsis, bacteremia, urinary infection, endocarditis, and peritonitis, especially in immunocompromised individuals (Aisenberg et al., 2004). Moreover, this organism can colonize various medical devices, such as disinfectant-soaked unwoven cleaning cloth (Oie et al., 2012), intravascular pressure transducer (Gahrn-Hansen et al., 1988), and chlorhexidine (Vu-Thien et al., 1998). To distinguish different Achromobacter strains, various methods have been applied. Similar to OXA-50-like enzymes from P. aeruginosa or OXA-51/69 from A. baumannii, the bla gene is a known characteristic of Achromobacter (Doi et al., 2008; Turton et al., 2011). Additionally, multilocus sequence typing (MLST) is one of the best methods for use in epidemiological studies in the world. There are more than 300 STs in the MLST database distributed across the world. However, due to the low incidence of Achromobacter infections, no clone complex has been reported. Elderly patients often have underlying diseases and frequently suffer from chronic infections, which may result in continuous exposure to various types of antibiotics. This exposure may contribute to antibiotic resistance. Based on previous studies, integrons and the inborn RND-Type Multidrug Efflux Pump (Bador et al., 2011) are the main reasons for antibiotic resistance. Various integrons (intI/intII) have been detected (Traglia et al., 2012). Additionally, extended-Spectrum β-Lactamases (ESBL) and metallo-b-lactamase (MBL) production by Achromobacter spp. has been detected in the last decade. In Europe, bla and bla inserted in integrons were found in Achromobacter spp. (Neuwirth et al., 2006; El Salabi et al., 2012). Various subtypes of bla have been detected in integron I in Asia and Europe (Riccio et al., 2001; Shin et al., 2005; Sofianou et al., 2005). Infections, pandemic or sporadic, are often related to the location of resistance genes (chromosome/plasmid). Thus, the insertion of a new bla-type gene in plasmids in A. xylosoxidans has attracted wide attention because it may spread easily (Yamamoto et al., 2012). Moreover, the inherent bla genes may result in a higher level of OXA-114-mediated-lactam resistance because of the insertion sequence elements (Doi et al., 2008). Therefore, Achromobacter spp. is an emerging pathogen and is becoming a reservoir for horizontal genetic transfer elements involved in spreading antibiotic resistance (Traglia et al., 2012). Hospital-acquired pneumonia (HAP) due to Achromobacter spp. has emerged as a substantial concern in recent years. Pulmonary involvement has been frequently reported in cases with underlying disease, especially in cystic fibrosis (CF) (Dunne and Maisch, 1995; Ferroni et al., 2002). In CF patients, A. xylosoxidans isolated from sputum increased gradually (Zemel et al., 2000; Liu et al., 2002). However, CF is a rare disease in China. In non-CF patients, several cases of pneumonia have been reported in patients with underlying malignancy (Aisenberg et al., 2004), those with IgM deficiency (Dworzack et al., 1978) and those on mechanical ventilation (Chandrasekar et al., 1986). Additionally, approximately half of these non-CF patients originated from the community, which may be related to the soil and aquatic environments (Swenson and Sadikot, 2015). However, HAP due to Achromobacter spp. in the elderly is rare. The features of this organism in the elderly need to be urgently studied. Therefore, this study aimed to understand the clinical characteristics, epidemiology, biofilm production and integrons of Achromobacter spp. in elderly patients with HAP.

Materials and Methods

Patients

Fifteen patients with HAP due to Achromobacter spp. treated in a geriatric ward in China from September 2008 to May 2012 were enrolled in this study. The diagnostic criteria of HAP were as described previously (Rotstein et al., 2007). Patient demographics and clinical characteristics (underlying disease, invasive manipulation, therapy, and mortality) were collected. The Acute Physiology and Chronic Health Evaluation II (APACHE II), Sequential Organ Failure Assessment (SOFA) score and Clinical Pulmonary Infection Score (CPIS) were evaluated within the first 24 h. Chronic infection was defined as a positive sputum culture on at least three occasions over a 6-month period, as previously suggested (Trancassini et al., 2014).

Microbial Identification and bla Analysis

Achromobacter spp. was cultured from sputum or aspirations more than twice and was the dominant species in the culture. All the strains were identified by the API 20 NE system and the Vitek II system as described previously (Otto-Karg et al., 2009; Tena et al., 2014). Species identification was confirmed by 16S ribosomal RNA gene sequencing (Mellmann et al., 2003). To further classify this organism, a specific PCR based on the detection of bla was performed (Turton et al., 2011).

Multilocus Sequence Typing

The primers and reaction conditions of seven housekeeping genes (nusA, rpoB, eno, gltB, lepA, nuoL, nrdA) were designed by searching Pubmlst[1]. Allelic profiling and ST determination were also performed through the above website. Additionally, phylogenetic analysis of housekeeping genes and eBURST analysis were performed. The concatenation of the seven housekeeping genes (total of 2249 bp) of Achromobacter spp. was performed. A dendrogram was constructed from the concatenated sequences by the neighbor-joining method (MEGA 6.05). The eBURST analysis was conducted using eBURST V3.

Biofilm Production Assay

All isolates were individually cultured overnight in M-H medium (OXOID). A monoclonal sample from the M-H medium was mixed with LB medium to prepare a bacterial suspension of 0.5 units. Bacterial suspensions (200 μl) were inoculated in a 96-well plate followed by 48 h of incubation at 37°C in a bacterial incubator (German He Liman). Plankton bacteria were removed by washing three times with distilled water every 30 s. The wells were dyed at room temperature for 5 min and then incubated with 200 μl of 1% Crystal Violet dye for 20 min. They were then washed twice with distilled water and dried at 37°C for 30 min. Two hundred microliters of 95% ethanol was added into each well, and the optical density (OD) at 570 nm was measured in a microtiter auto reader (Thermo Fisher Scientific, US) (Trancassini et al., 2014; Zhang et al., 2016). ATCC Escherichia coli DH5a (Ac) was used as a negative control. The established criteria (four levels of biofilm-forming ability) were the following: (1) N: no biofilm producer (-), A ≤ Ac; (2) W: weakly positive (++), Ac < A ≤ 2Ac; (3) M: moderately positive (++), 2Ac < A ≤ 4Ac; and (4) S: strongly positive (+++), A > 4Ac (Stepanović et al., 2007).

Susceptibility Testing

Antimicrobial susceptibility testing was conducted using the microbroth dilution method as described previously (Yamamoto et al., 2012). The etest was employed for polymyxin B in M-H medium (OXOID) (Table ). The results were interpreted using the 2015 Clinical and Laboratory Standards Institute (CLSI) guidelines. The microbes feature of 15 cases.

Bla Analyses

The dendrogram analysis of bla was performed using MEGA (version 6.05). The alignment used for the tree calculation and various amino acid sequences of OXA enzymes were performed with Clustal X (version 1.83). To determine whether different subtypes of bla relate to different antibacterial spectra, antibacterial spectra were compared among these subtypes.

PCR

Total DNA was prepared and used as a template for PCR reactions. PCR screening for integrase (intI1, intI2, and intI3) genes was performed as described previously (Yamamoto et al., 2012). The primers used in this study are shown in Supplementary Table S1 (Woodford et al., 2006; Poirel et al., 2011; El Salabi et al., 2012; Poirel et al., 2012). The primers designed for various regions were Pf: GCATCCAAGCAGCAAG and Pr: AAGCAGACTTGACCTGA. PCR was performed using the Pyrobest DNA Polymerase according to the manufacturer’s instructions (Takara). PCR products were resolved on 1.0% agarose gels, stained with ethidium bromide, and photographed with UV illumination. The PCR products were then sequenced after purifying the DNA by using the Gel Extraction Kit according to the manufacturer’s directions (Axygen). The products were sequenced by Major Biological Medicine Technology Co Ltd in Shanghai.

Nucleotide Sequence Accession Numbers

The nucleotide sequences of the various regions in the integrons reported in this study were submitted to the NCBI[2] and assigned the accession numbers KT454532, KT719385, KT719386, and KT719387 (Figure ). Schematic representation of the class 1 integron gene cassettes in .

Results

Clinical Characteristics

These infections first occurred in 2008, and 2, 3, 5, 1, and 3 infections happened per year from 2008 to 2012, respectively. Patient characteristics are summarized in Table and Supplementary Table S2. In total, 14 males and 1 female were included in this study. The mean age was 88.8 ± 5.4 years. All the patients had more than 3 diseases, and 10 of them had 3 or more catheters. The primary underlying diseases were coronary heart disease (CHD) and chronic pulmonary disease. Eleven patients received proton pump inhibitors (PPI), three patients received corticosteroids and two received chemotherapy. Almost all these patients were treated with various antimicrobial therapies within the previous 14 days. Chest imaging of all patients showed patchy exudation. Pleural effusion was found in 33.3% (5/15) of cases, and one case showed consolidation. The mean APACHE II, SOFA and CPIS scores were 23.4 ± 7.7, 7.4 ± 2.7, and 7.6 ± 1.64, respectively. Twelve patients were given a different antibiotic regimen after the antimicrobial susceptibility test. Nine patients were treated by mechanical ventilation. Three patients had chronic infections lasting more than 1 year. Of those with infections, 10 were alive, and 5 (33.3%) died 30 days after infection. The fatal cases were more likely to have sepsis (n = 3). Detailed clinical features of HAP with Achromobacter spp. infection.

Diversity of bla

All Achromobacter spp. strains had positive results for the amplification of bla (Figure ). To further study the sequence diversity of bla in Achromobacter spp., amino acid sequence comparison of the bla gene was conducted and an evolutionary tree were constructed (Figure ). The most frequent type was bla, which accounted for 53.3% (8/15) of isolates. Other genes included bla (three cases), bla (three cases) and bla (one case). There were amino acid differences among all of the isolates. Amino acid sequence differences in the OXA enzymes described in this study. Dendrogram analysis of OXA enzymes in . The tree was inferred for various bla types, bla, and bla using the neighbor-joining method.

MLST and BF

Based on MLST, four cases belonged to ST5, and these cases were distributed in two separate buildings of the hospital. Six new STs were detected (ST306, 307, 311, 312, 313, 314). Five cases belonged to ST306, and 2 belonged to ST313 (Figure ). Phylogenetic analysis of housekeeping genes showed that there was a less obvious relationship between ST5 and ST314 (Figure ), which were found in cases from the general medicine department in a different building from where the other STs were isolated. Additionally, all STs available in the database were analyzed via eBURST. The results show that ST313 belongs to the ST1 CC (clone complex), and HAP caused by this organism may occur sporadically (Figure ). The distribution of the 15 patients by admission department and year. CCU, cardiac intensive care unit; RICU, respiratory intensive care unit. General Medicine (the blue underline) is in another building. The same sequence type is shown in the same color square. The square represents male gender. The star represents female gender. Neighbor-joining dendrogram of concatenated sequences of seven housekeeping genes from the MLST database. eBRUST analysis of all STs of . Circles represent different STs; blue represents a primary founder, yellow represents a subgroup founder, red denotes STs found in the present study dataset only. All strains were able to produce a biofilm on 96-well plates (Table ). Nearly half of the strains were moderate biofilm producers, four strains were strong producers, and five strains were weak producers.

Antibiotic Resistance and Integron Variable Region

All strains were resistant to aminoglycosides, aztreonam, nitrofurantoin, and third- and fourth-generation cephalosporins (except ceftazidime and cefoperazone). Approximately half of these strains were resistant to ciprofloxacin, tetracycline and imipenem, but the sensitivity to piperacillin/tazobactam and meropenem was close to 70%. All the bla type strains showed high resistance to cefepime, cefotaxime and ceftriaxone and high sensitivity to piperacillin and piperacillin/tazobactam. It is interesting that both bla and bla strains are resistant to ciprofloxacin and show higher resistance to carbapenems than other subtypes (Table , Figure ). However, due to the small sample, a large sample analysis should be conducted to further examine this finding. The antibacterial spectrum of bla strain. The antibacterial spectrum of 1: bla, 2: bla, 3: bla 4: bla CAZ, ceftazidime; FEP, cefepime; CTX, cefotaxime; CRO, ceftriaxone; CPZ, cefoperazone; LEV, levofloxacin; CIP, ciprofloxacin; IPM, imipenem; MEM, meropenem; PIP, piperacillin; TZP, piperacillin/tazobactam. We examined three types of integrons (intI, intII, intIII), and all the strains had intI, but neither intII nor intIII were found. In the variable region in intI, aadB + aadA2 were detected in 10 strains, aadB was inserted in two strains, dfrA17+ aacA4 in one isolate, and bla+aac(6′)-II + aadB in one isolate (Supplementary Figure S1).

Discussion

Achromobacter spp. have been frequently detected by the cystic pulmonary fibrosis (CF) center in recent years (Lambiase et al., 2011; Pereira et al., 2011; Amoureux et al., 2013b; Llorca Otero et al., 2016). A study showed that colonization mostly occurred in elderly patients who had more pronounced lung damage and poorer lung function (De Baets et al., 2007). Chronic pulmonary disease and respiratory tract infections often occur in elderly patients. In our study, elderly patients had more than three diseases, particularly CHD, chronic pulmonary disease and cerebrovascular disease. Additionally, 10 had 3 or more indwelling catheters. These catheters may contribute to the higher APACHE II and SOFA scores. The mortality rate was 33.3% (5/15), which is higher than that in other studies (Gómez-Cerezo et al., 2003; Aisenberg et al., 2004). Piperacillin/tazobactam and meropenem showed a strong ability to treat the infection, consistent with the in vitro susceptibility tests. In our study, nine patients (60%) received mechanical ventilation. This organism can colonize humidifiers, which is an issue that needs to be addressed when a patient receives mechanical ventilation (Tena et al., 2005). More than 300 types of Achromobacter spp. have been recorded in the MLST database. ST5 was first cultured from a CF patient in USA. In our hospital, four cases were infected by this type from 2009 to 2012 in two buildings. These patients did not appear to be clustered in space or time. Moreover, the MIC of carbapenems for ST5 was lower. From 2008 to 2010, ST306 was detected in the Respiration and CCU. Interestingly, the same ST showed various antibiotic-resistance spectra, indicating different resistance mechanisms. The other STs (ST307, ST311, ST312, ST313, and ST314) did not appear to be clustered in space or time. Additionally, the location and timing were not consistent with the six non-clustered cases. However, no strain was detected from doctors’ hands or from medical equipment. The source of their infection could not be determined. Two strains (ST313) showed higher MIC for cephalosporins, quinolones and carbapenems, which should be considered in clinical practice. It has been proposed that bla is an inherent gene for Achromobacter xylosoxidans (Turton et al., 2011). Additionally, the diversity of bla has been reported (Amoureux et al., 2013a). Bla, bla, bla and bla were also detected in our study, which confirmed the diversity of this gene. We have listed the similarities and differences in amino acids among these genes in our isolates. Further studies are needed to understand the function of these differences. In our study, the strains isolated from patients who were supported by mechanical ventilation had stronger biofilm production. Additionally, the strong biofilm producers (No. 8, 10, 11) showed higher MIC of carbapenems. These characteristics may be shared by other Gram-negative biofilm producers. Various regions of integrons can carry various resistance genes. In Argentina, class 1 integrons and class 2 integrons were detected in an Achromobacter spp., including various antibiotic-resistant genes (Traglia et al., 2012). In the present study, only class 1 integrons were detected, and all strains were resistant to aminoglycosides, consistent with the three types of genes (aadB, aadA2 and aacA4) detected in the integron. The overuse of antibiotics may be a reason for the increasing opportunistic infections with resistant microorganisms (Tan et al., 2002). In vitro, these isolates showed high sensitivity to trimethoprim/sulfamethoxazole, polymyxin B, meropenem and piperacillin/tazobactam. In clinical practice, due to the hepatic and renal toxicity of trimethoprim/sulfamethoxazole and polymyxin B, meropenem and piperacillin/tazobactam are frequently used in therapy. Additionally, in our study, nine patients survived after meropenem and piperacillin/tazobactam therapy. However, four isolates showed high resistance to imipenem in vitro. In a previous study, the bla located in integron I was reported in both Asia and Europe (Riccio et al., 2001; Shin et al., 2005; Sofianou et al., 2005). Additionally, a new type of bla inserted in plasmids was detected in A. xylosoxidans, which could easily trigger a pandemic of carbapenem-resistant isolates (Yamamoto et al., 2012). Unfortunately, metallo-b-lactamase (MBL) gene cassettes involved in carbapenem resistance were not detected in the integrons. Other mechanisms may account for the carbapenem resistance observed in this study. Thus, whole genome sequencing may be needed for further study. Many studies showed that dfrA was frequently detected in integrons (Yu et al., 2003, 2004). In our study, dfrA17 was found in integron I, which was once detected in patients with urinary tract infection from another Gram-negative organism in Korea. However, the clinical specimens of our patients were sputum samples. The spread of dfrA17 may be related to the plasmid (Yu et al., 2003). The bla gene was first reported in Achromobacter spp. This gene can induce carbenicillin-hydrolyzing beta-lactamases aimed at carboxypenicillins, ureidopenicillins and cefsulodin. These enzymes belong to molecular class A and functional group 2c (Bush et al., 1995), which can be frequently detected in Gram-negative organisms. These results indicate that this organism may be a reservoir of horizontal genetic transfer elements for spreading antibiotic resistance (Collis and Hall, 1995). This study has several limitations. First, it is a small retrospective study conducted over 5 years. Therefore, the source of infection could not be determined, and our results cannot be generalized to other populations. Second, these cases of Achromobacter spp. in China are not routinely reported. Third, the mechanism of resistance to carbapenems was unclear. Whole genome sequencing may be needed in further studies.

Author Contributions

XF: study design, data collection, data analysis, writing of the manuscript; CL: study design, data collection and analysis, writing of the manuscript. Chao L: study design, data collection and analysis, writing of the manuscript; FP: data collection and analysis, writing of the manuscript; JG: data analysis, writing of the manuscript; YJ: data analysis, writing of the manuscript; LQ, YJ, and WY: data collection; All authors have read and approved the final version of the manuscript.

Conflict of Interest Statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Table 1

The microbes feature of 15 cases.

NO.ANGMTOBATMCAZFEPCTXCROCPZLEVCIPIPMMEMTCYPBPIPTZPSXTFInt.VRblaOXA-114STBF
1>64>16>16>644>64>64>6484416484<164/2<2/38>512IaadB + aadA2blaOXA-114q307W
2>64>16>16>64>32>64>64>6432222121<164/4>4/76256IdfrA17 + aacA4blaOXA-114q306M
3>64>16>16>64432>64>64410.54281<164/2<2/38>512IaadB + aadA2blaOXA-114h5W
4>64>16>16>6416>64>64>64322>480.5>162<164/4<2/38>512IaadB + aadA2blaOXA-114q306W
5>64>16>16>64>32>64>64>64>64>8>448>164<164/4>4/76256IaadBblaOXA-114h5M
6>64>16>16>644>64>64>6444>42282<164/2<2/38>512IaadBblaOXA-114r311W
7>64>16>16>648>64>64>6484416481<164/4<2/38>512IaadB + aadA2blaOXA-114q312W
8>64>16>16>6416>64>64>64324>464>128>1686464/4<2/38256IaadB + aadA2blaOXA-114r313S
9>64>16>16>648>64>64>6432428882128128/4<2/38>512IaadB + aadA2blaOXA-114h5M
10>64>16>16>6416>64>64>64324>4>128>128>16163232/4<2/38>512IaadB + aadA2blaOXA-114t314S
11>64>16>16>64>3232>64>648>8>46464232<164/2>4/76>512IaadB + aadA2blaOXA-114q306S
12>64>16>16>648>64>64>64>642216482<164/4<2/38256IaadB + aadA2blaOXA-114q306M
13>64>16>16>648>64>64>6448>444>162<164/4<2/38>512IaadB + aadA2blaOXA-114q5S
14>64>16>16>648>64>64>6464844448128128/4<2/38>512IblaPSE-1 + aac(6′)-II + aadBblaOXA-114q306M
15>64>16>16>64>32>64>64>64>6484>128>128>162<168/4<2/38>512IaadB + aadA2blaOXA-114r313M
Table 2

Detailed clinical features of HAP with Achromobacter spp. infection.

No.Sex/AgeComorbiditiesTubePredisposing factorAntibiotic use in 14 daysClinical presentationEmpiric therapySwitched therapyMechanical ventilationAPACHE IICPISSOFACompli cationsOutcome at 30 daysChest Imaging
1M/88CHD; Chronic bronchitis; Hypertension; MalignancyCVCPPI; Corticosteroids; ChemotherapyTZP; Voriconazale; ONZ; IPM; Ceftriaxonze;Fever(Tmax38.4°C); Cough; Purulent SputumLEVMEMNon1796RFSurvivedExudation(R); consolidation (L)
2M/89COPD;OPT; Hypertension; Arrhythmia;CVC; Ureter; Stomach tube; Tracheostomy cannulaPPIMIN;TZP;IPMFever(Tmax38.5°C) Purulent SputumSCFMEMInvasive251111RFSurvivedBilateral exudation;
3M/97Cerebrovascular disease; Hypertension; CHD;Chronic bronchitis; Post operation;Stomach tube; CVC; Tracheostomy cannulaNonNonPurulent SputumTZPTZPNon1565NonSurvivedBilateral exudation; Pleural effusion(L)
4M/75ILD;CHD; Diabetes; CRF;Chronic bronchitis; Hypertension; Cerebrovascular disease; Arrhythmia;CVC; Ureter; Stomach tube; Tracheostomy cannulaPPITZP, SXT, MXF, Linezolid; VoriconazoleFever(Tmax38.0°C); Purulent SputumSCFMEMNon2889RFSurvivedExudation(R)
5M/88CHD; CRF; Diabetes Hypertension; Arrhythmia;CVC; Ureter; Stomach tube; Nasotracheal intubationPPIMEM; CAZ; MNZ; CaspofunginFever(Tmax38.0°C); Chill; Cough; Purulent SputumLEVTZP+MEMNon32107SepsisDiedBilateral exudation;
6M/85CHD; Diabetes; Chronic bronchitis; Hypertension; Cerebrovascular disease;Stomach tubeNonCefditoren pivoxilPurulent SputumMXFMEMNon1354HyoxemiaSurvivedExudation(L)
7M/95ILD; CHD; Hypertension; Arrhythmia; Diabetes; Cerebrovascular disease;CVC; Stomach tubePPINonDyspnea; Cyanosis; Cough; Purulent SputumFMOXMXFNon1369RFSurvivedBilateral exudation
8M/87CHD; Hypertension; ArrhythmiaCVC; Ureter; Stomach tube; Tracheostomy cannulaPPI; CorticosteroidsMEM;MIN;SXT; FMOX;ONZFever(Tmax38.0°C); Chill; Purulent SputumIPMCAZ+TZPInvasive2766RFSurvivedBilateral exudation; Pleural effusion(L)
9M/93Chronic bronchitis CHD; Diabetes Cerebrovascular diseaseCVC; Ureter; Stomach tube; Tracheostomy cannulaNonSCF;IPM; TZP; Linezolid; CIP; ONZ; Voriconazole; CaspofunginPurulent SputumMXFMEM+CAZNon-Invasive switch to Invasive1787Sepsis shockDiedBilateral exudation; Bilateral effusion
10M/93COPD;CHD; CRF; Diabetes Hypertension; Cerebrovascular disease;CVC; Ureter; Stomach tube; Tracheostomy cannulaPPIMXF; Linezolid; VoriconazoleFever(Tmax38.5°C); Chill; Purulent SputumIPMCAZ+TZPInvasive35812SepsisDiedBilateral exudation
11F/82Chronic bronchitis;CHD; Diabetes; Cerebrovascular diseaseCVC; Ureter; Stomach tube; Tracheostomy cannulaNonLEV;SCF;MEM; CaspofunginFever(Tmax38.2°C); Purulent SputumIPMTZP+MINInvasive1877ARDSDiedBilateral exudation; Bilateral effusion
12M/89CHD; ILD; Chronic bronchitis; Malignancy; Cerebrovascular diseaseCVC; Stomach tubePPI; ChemotherapyEtimicin;Purulent SputumMEMMEMNon-Invasive36810MOFDiedExudation(R); Pleural effusion(R)
13M/92CHD;OPT; Chronic bronchitis; Hypertension; Cerebrovascular diseaseStomach tubePPIMEM;TZP;MIN; CaspofunginFever(Tmax37.8°C); Purulent SputumIPMIPMInvasive2164NonSurvivedExudation(R)
14M/89COPD;ILD; CHF Cerebrovascular diseaseCVC; Stomach tube; Tracheostomy cannulaPPIFMOXPurulent SputumSCFIPM+MINNon-Invasive switch to invasive2689RFSurvivedBilateral exudation
15M/90COPD;CHD; CRF; Diabetes Hypertension; Arrhythmia; Cerebrovascular disease;CVC; Ureter; Stomach tube; Tracheostomy cannulaPPI; CorticosteroidsMXF; Linezolid, VoriconazolePurulent SputumIPMTZPNon-Invasive2887RFSurvivedBilateral exudation
Table 3

The antibacterial spectrum of bla strain.

TotalCAZ
FEP
CTX
CRO
CPZ
LEV
CIP
IPM
MEM
PIP
TZP
NumberNRRNRRNRRNRRNRRNRRNRRNRRNRRNRRNRR
blaOXA-114q86208080862532644717171
blaOXA-114h32103030321212130302121
blaOXA-114r32103030321210312123030
blaOXA-114t11001010110100101011010
  43 in total

1.  Achromobacter xylosoxidans in cystic fibrosis: prevalence and clinical relevance.

Authors:  Frans De Baets; Petra Schelstraete; Sabine Van Daele; Filomeen Haerynck; Mario Vaneechoutte
Journal:  J Cyst Fibros       Date:  2006-06-21       Impact factor: 5.482

2.  Outbreak of infection with Achromobacter xylosoxidans from contaminated intravascular pressure transducers.

Authors:  B Gahrn-Hansen; P Alstrup; R Dessau; K Fuursted; A Knudsen; H Olsen; H Oxhøj; A R Petersen; A Siboni; K Siboni
Journal:  J Hosp Infect       Date:  1988-07       Impact factor: 3.926

Review 3.  A functional classification scheme for beta-lactamases and its correlation with molecular structure.

Authors:  K Bush; G A Jacoby; A A Medeiros
Journal:  Antimicrob Agents Chemother       Date:  1995-06       Impact factor: 5.191

4.  Achromobacter xylosoxidans infection in an adult cystic fibrosis unit in Madrid.

Authors:  Laura Llorca Otero; Rosa Girón Moreno; Buenaventura Buendía Moreno; Claudia Valenzuela; Alba Guiu Martínez; Teresa Alarcón Cavero
Journal:  Enferm Infecc Microbiol Clin       Date:  2015-06-29       Impact factor: 1.731

5.  Ribosomal DNA-directed PCR for identification of Achromobacter (Alcaligenes) xylosoxidans recovered from sputum samples from cystic fibrosis patients.

Authors:  Lixia Liu; Tom Coenye; Jane L Burns; Paul W Whitby; Terrence L Stull; John J LiPuma
Journal:  J Clin Microbiol       Date:  2002-04       Impact factor: 5.948

Review 6.  OXA-48-like carbapenemases: the phantom menace.

Authors:  Laurent Poirel; Anaïs Potron; Patrice Nordmann
Journal:  J Antimicrob Chemother       Date:  2012-04-11       Impact factor: 5.790

7.  Characterization of a naturally occurring class D beta-lactamase from Achromobacter xylosoxidans.

Authors:  Yohei Doi; Laurent Poirel; David L Paterson; Patrice Nordmann
Journal:  Antimicrob Agents Chemother       Date:  2008-03-24       Impact factor: 5.191

8.  Alcaligenes infection in cystic fibrosis.

Authors:  Kenneth Tan; Steven P Conway; Keith G Brownlee; Christine Etherington; Daniel G Peckham
Journal:  Pediatr Pulmonol       Date:  2002-08

9.  Epidemiology and resistance of Achromobacter xylosoxidans from cystic fibrosis patients in Dijon, Burgundy: first French data.

Authors:  Lucie Amoureux; Julien Bador; Eliane Siebor; Nathalie Taillefumier; Annlyse Fanton; Catherine Neuwirth
Journal:  J Cyst Fibros       Date:  2012-09-01       Impact factor: 5.482

10.  Evaluation of RIDOM, MicroSeq, and Genbank services in the molecular identification of Nocardia species.

Authors:  Alexander Mellmann; Joann L Cloud; Sebastian Andrees; Kym Blackwood; Karen C Carroll; Amin Kabani; Andreas Roth; Dag Harmsen
Journal:  Int J Med Microbiol       Date:  2003-11       Impact factor: 3.473

View more
  4 in total

Review 1.  Achromobacter Infections and Treatment Options.

Authors:  Burcu Isler; Timothy J Kidd; Adam G Stewart; Patrick Harris; David L Paterson
Journal:  Antimicrob Agents Chemother       Date:  2020-10-20       Impact factor: 5.191

Review 2.  Achromobacter xylosoxidans and Stenotrophomonas maltophilia: Emerging Pathogens Well-Armed for Life in the Cystic Fibrosis Patients' Lung.

Authors:  Quentin Menetrey; Pauline Sorlin; Estelle Jumas-Bilak; Raphaël Chiron; Chloé Dupont; Hélène Marchandin
Journal:  Genes (Basel)       Date:  2021-04-21       Impact factor: 4.096

3.  Achromobacter spp. in a Cohort of Non-Selected Pre- and Post-Lung Transplant Recipients.

Authors:  Cornelia Geisler Crone; Omid Rezahosseini; Hans Henrik Lawaetz Schultz; Tavs Qvist; Helle Krogh Johansen; Susanne Dam Nielsen; Michael Perch
Journal:  Pathogens       Date:  2022-01-28

4.  An 18-Year Dataset on the Clinical Incidence and MICs to Antibiotics of Achromobacter spp. (Labeled Biochemically or by MAL-DI-TOF MS as A. xylosoxidans), Largely in Patient Groups Other than Those with CF.

Authors:  Claudio Neidhöfer; Christina Berens; Marijo Parčina
Journal:  Antibiotics (Basel)       Date:  2022-02-25
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.